Conference Magazine - GoingPublic.de - Deutsches Eigenkapitalforum

Capital Seeking Companies
Profile
Founded in 2006
Number of employees 25
Equity (in EUR million) -
Financing needs (in EUR million) 7.0
Positive result from -
Revenues in 2010 (in EUR million) -
Revenues in 2011 (in EUR million) -
Revenues in 2012 (e) (in EUR million) -
Revenues in 2013 (e) (in EUR million) -
Contact
Contact person Mag. Thomas Exel
Phone: +43-(0) 6 99-19 07 05 55
E-mail: exel@glucopearl.com
Website: www.glucopearl.com
Address: Industriepark 1
8772 Traboch
Austria
Business field
4a medicom GmbH is developing and commercialising an
innovative system for measuring blood glucose. Unlike
other commonly used systems, it enables the measurement
to be taken by combining blood acquisition and blood sugar
measurement − in just a single step and “at the touch of a
button”. Diagnostic self-testing is the fastest-growing
sector in the in vitro diagnostics market, which currently
amounts to more than USD 35 billion worldwide. Especially
attractive is the approximately USD 8 billion-large global
market for self-testing blood sugar levels (“self-monitoring
of blood glucose”, also known as “SMBG” for short) and
the approximately USD 1 billion-large market for glucose
measurement by professional personnel (“point of care”, or
“POC” for short). 4a medicom addresses both these
markets with the innovative GlucoPEARL.
Page 124 Deutsches Eigenkapitalforum 2012
4a medicom GmbH
Pharmaceuticals and health /
medical technology
Strategic market position
An entirely novel and prototyped concept is the consolidation
(unitisation) of all testing utensils and steps into a single
disposable test device. This development offers unparalleled
simplicity, speed and safety with regard to test
performance and disposal.
Management
Reinhard Hafellner is the founder of
4a Group. He studied Plastics Engineering
and Polymer Science at the
University for Applied Sciences in
Leoben, Austria. Among others, he is
the founder of a company that produces
loudspeaker components for
mobile phones (which has a global
markt share of about 15%).
Thomas Exel, COO
Thomas Exel, CCO, has more than 6
years of senior management experience
within a diabetes-focused European sales organisation
and therefore brings to 4a medicom numerous national
and international contacts in the diabetes environment.
Sylvia Fauland, CFO since July 2012, has more than 15
years of senior management experience in multinational
listed companies in the areas of finance, treasury and
acquisitions.
Planned investment, shareholders/investors
The capital invested up to this point has comprised funding
from the circle of founders, grants and A-series financing
with an investor consortium made up of three financial investors
in 2010. Funding from B-series financing with
volumes of approximately EUR 7 million will be mainly
invested in the manufacturing stage of the product and in
building up distribution. A major part of the investment is
scheduled for production with outsourcing partners.
The 4a medicom GmbH shareholders are the two founders
(53%), three venture capital companies (44.5%) and some
private investors (2.5%).